Lucid Diagnostics Inc.
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage medical diagnostics company focused on detecting esophageal precancer and cancer in people at risk, particularly those with gastroesophageal reflux disease. Its EsoGuard Esophageal DNA Test analyzes cells collected with the EsoCheck swallowable device, which… From the company’s description.
Over the twelve months to Jun 30, 2026, Lucid Diagnostics Inc. reported revenue of $5.45M, up 24.9% from a year earlier, and a net loss of $52.26M. Its operating margin was −930.8%, and operations used $46.87M in cash. In fiscal 2025, it reported revenue of $4.71M, up 8.3% from fiscal 2024, and a net loss of $58.01M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Lucid Diagnostics Inc. does
In the company’s own words
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage medical diagnostics company focused on detecting esophageal precancer and cancer in people at risk, particularly those with gastroesophageal reflux disease. Its EsoGuard Esophageal DNA Test analyzes cells collected with the EsoCheck swallowable device, which gathers surface cells from a targeted area of the esophagus; the test is performed in LucidDx Labs’ CLIA-certified, CAP-accredited laboratory. The company serves patients and healthcare providers through its own and satellite testing centers, physician offices, mobile testing, health-system programs, employer and union contracts, cash-pay services, and telemedicine referrals. Lucid reports one business focused on commercializing EsoGuard and EsoCheck. It also operates CapNostics, LLC, identified as a subsidiary. EsoCheck received FDA 510(k) clearance, while EsoGuard is marketed as a laboratory-developed test. In 2025, the company reported real-world experience involving approximately 12,000 patients. Its brands include EsoGuard, EsoCheck, and Collect + Protect. Its website is https://www.luciddx.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1799011
- SIC
- 3841
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Lucid Diagnostics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Lucid Diagnostics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Lucid Diagnostics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Lucid Diagnostics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Lucid Diagnostics Inc.'s last four quarterly filings that the numbers alone won't show?”